Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event - Additional Information (Detail)

v3.7.0.1
Subsequent Event - Additional Information (Detail)
 1 Months Ended 3 Months Ended
May 10, 2017
USD ($)
Investor
$ / shares
shares
May 04, 2017
shares
May 10, 2017
USD ($)
$ / shares
shares
Mar. 31, 2017
shares
Dec. 31, 2016
shares
Subsequent Event [Line Items]          
Preferred stock, shares outstanding | shares       20,000,000 20,000,000
Operational changes related to employees, description       Eight lab employees supporting aspects of our lantibiotic research were let go with three lead senior scientists remaining as the Company seeks to employ external vendors dedicated to progressing the clinical development of our lantibiotic candidates under the leadership and oversight of our senior scientists including our Senior Vice President of Discovery Research, Dr. Martin Handfield.  
Subsequent Event [Member]          
Subsequent Event [Line Items]          
Number of accredited investors | Investor 3        
Subsequent Event [Member] | Class Two [Member]          
Subsequent Event [Line Items]          
Term of warrants 7 years        
Warrants exercise price per share | $ / shares $ 0.31   $ 0.31    
Subsequent Event [Member] | Equity Incentive Plan [Member]          
Subsequent Event [Line Items]          
Number of additional shares available for issuance under stock option plan | shares   1,500,000      
Subsequent Event [Member] | Intrexon [Member]          
Subsequent Event [Line Items]          
Debt instrument, term     2 years    
Debt instrument, simple interest rate 12.00%   12.00%    
Debt financing, first milestone payment, prior to amendment | $     $ 2,000,000    
Debt financing, first milestone payment, after amendment | $     $ 3,000,000    
Debt instrument amendment, description     The Company and Intrexon agreed to amend the first milestone payment on the ECC from a $2.0 million payment upon first dosing of a patient to a $3.0 million payment upon the earlier of (a) dosing of the last patient, in a phase II clinical trial, and (b) the twenty four (24) month anniversary of the dosing of the first patient in the phase II clinical trial. Simultaneously with the amendment to the ECC a similar amendment was put in place with respect to the Company’s Stock Issuance Agreement with Intrexon reflecting the milestone amendment.    
Subsequent Event [Member] | Series A Preferred Stock [Member]          
Subsequent Event [Line Items]          
Convertible shares of common stock | shares 12,000,000   12,000,000    
Fixed conversion price | $ / shares $ 0.25        
Preferred stock, shares outstanding | shares 12,000,000   12,000,000    
Voting rights No voting rights        
Subsequent Event [Member] | Series A Preferred Stock [Member] | Maximum [Member]          
Subsequent Event [Line Items]          
Gross proceed of preferred stock | $ $ 3,000,000        
Subsequent Event [Member] | Series A Preferred Stock [Member] | Preferred Stock Issued Upon Initial Closing [Member]          
Subsequent Event [Line Items]          
Gross proceed of preferred stock | $ $ 1,302,000        
Warrants to purchase common stock, issued | shares 4,621,037   4,621,037    
Subsequent Event [Member] | Series A Preferred Stock [Member] | Preferred Stock Issued Upon Second Closing [Member]          
Subsequent Event [Line Items]          
Gross proceed of preferred stock | $ $ 1,698,000        
Warrants to purchase common stock, issued | shares 6,024,124   6,024,124    
Subsequent Event [Member] | Unsecured Non-convertible Promissory Note [Member] | Intrexon [Member]          
Subsequent Event [Line Items]          
Unsecured promissory note | $ $ 2,400,000   $ 2,400,000